Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.

Abstract Inhibitors of integrin αvβ3 have been implicated in the treatment of a variety of diseases, including tumor metastasis, neovascularization, osteoporosis, and rheumatoid arthritis. It is therefore desirable to develop new types of small molecule inhibitors of integrin αvβ3. Here we describe the discovery of novel classes of small molecule inhibitors, via structure-based virtual screening, that target the ligand binding site of integrin αvβ3. Application of the docking procedure for screening of a commercially available compound database resulted in a 1774-fold reduction in the size of the screening set (88695 to 50 compounds) and gave a hit-rate of 14% upon biological evaluation (IC50 value ranging from 30 to 200 μM). The best hit, compound 37, 3,4-dichloro-phenylbiguanide, showed inhibitory activity, in a time- and dose-dependent manner, in both cell motility and angiogenesis assays. Based on the best hit, compound 37, a more effective derivative compound 62 has been identified. Furthermore, molecular graphics analyses of a series of substituted phenylbiguanides were carried out to predict the binding mode between the active compounds and integrin αvβ3. Our results indicate that the substituted phenylbiguanides might be involved in the inhibition of bivalent cation-mediated ligand binding of integrin αvβ3.

[1]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[2]  Chen Xu,et al.  Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening. , 2003, Bioorganic & medicinal chemistry letters.

[3]  F. Mitjans,et al.  Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells. , 2000, European journal of cell biology.

[4]  Andrea Vaupel,et al.  Biphenyls as potent vitronectin receptor antagonists. , 2002, Bioorganic & medicinal chemistry letters.

[5]  H. Deckmyn,et al.  Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. , 1994, Circulation.

[6]  G. Nicolson,et al.  Involvement of Integrin αvβ3 in Cell Adhesion, Motility, and Liver Metastasis of Murine RAW117 Large Cell Lymphoma , 1996 .

[7]  V. Quaranta,et al.  Activation of the Integrin Involves a Discrete Cation-binding Site That Regulates Conformation (*) , 1996, The Journal of Biological Chemistry.

[8]  S. Rosenfeld,et al.  Glioma migration can be blocked by nontoxic inhibitors of myosin II. , 1999, Cancer research.

[9]  K. Erhard,et al.  Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. , 1999, Journal of Pharmacology and Experimental Therapeutics.

[10]  J. Heino,et al.  αV integrin promotes in vitro and in vivo survival of cells in metastatic melanoma , 2004, International journal of cancer.

[11]  A. Callow,et al.  Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA , 1994 .

[12]  Andrea Vaupel,et al.  Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas. , 2003, Bioorganic & medicinal chemistry letters.

[13]  M. Kitajima,et al.  The Relationship Between Bone Metastasis from Human Breast Cancer and Integrin αvβ3 Expression , 2005 .

[14]  H. Kleinman,et al.  Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro , 1989, Cell.

[15]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[16]  J. Nip,et al.  The role of the integrin vitronectin receptor, αvβ3 in melanoma metastasis , 1995, Cancer and Metastasis Reviews.

[17]  M. Rosenblatt,et al.  Blockade of osteoclast‐mediated bone resorption through occupancy of the integrin receptor: A potential approach to the therapy of osteoporosis , 1994, Journal of cellular biochemistry.

[18]  Chandra L. Theesfeld,et al.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M A Horton,et al.  A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. , 1997, The Journal of clinical investigation.

[20]  G. Appleyard,et al.  Expression of integrin subunits αv and β3 in acute lung inflammation , 2004, Histochemistry and Cell Biology.

[21]  M. Ginsberg,et al.  Integrin-mediated cell adhesion: the extracellular face. , 1994, The Journal of biological chemistry.

[22]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[23]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.

[24]  G. Giannelli,et al.  Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. , 2002, Journal of cell science.

[25]  R. Wilder,et al.  Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases , 2002, Annals of the rheumatic diseases.

[26]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 , 2001, Science.